Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. He is currently President & CEO of Sunshine Biopharma and has an appointment as Adjunct Professor at Universite du Quebec. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 184.108.40.206) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap. At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.
Mr. Sebaaly has over 20 years of experience in engineering, development and commercialization of emerging technologies worldwide. Mr. Sebaaly was appointed as our Chief Financial Officer, Secretary and a Director of our Company on October 15, 2009. Since 2001, Mr. Sebaaly has been self-employed as a business consultant, primarily in the biotechnology and biopharmaceutical sectors. He held a number of senior executive positions in various areas including, financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. In the area of marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing and business development plans, designed marketing communications and launched market penetration programs. Mr. Sebaaly was a cofounder of Advanomics Corporation with Dr. Slilaty. Mr. Sebaaly graduated from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987.
Dr. Merzouki is an accomplished scientist with over 20 years of experience in virology and immunology. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. He was appointed as a Director and Chief Operating Officer of Sunshine Biopharma in February 2015. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology. Prior to joining Sunshine, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. He also worked in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and production and purification of recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. In addition to his academic expertise, Dr. Merzouki has a strong worldwide network of business and financial relationships.
© 2009 Sunshine Biopharma Inc., All Rights Reserved.